peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Scientist pipetting in a petri dish

Our pipeline and products

We believe there is significant opportunity for our clinically validated IgG-cleaving enzyme technology to serve as a treatment option across several therapeutic areas and indications


We are developing a broad therapeutic pipeline with potential applications across transplantation, autoimmune diseases, gene therapy and oncology indications to address significant unmet medical needs.

Our pipeline


Further to the ongoing clinical programs in kidney transplant, AMR, and autoimmune diseases, we are investigating in preclinical settings the use of our technology platform as a pre-treatment in gene therapy, in combination with cancer immunotherapy, as well as developing our next generation enzyme for repeat dosing.


Scientific collaborations

In our mission to help patients with rare immunological conditions, we see the collaboration with scientific and medical experts around the world as a key component for the successful outcome of our work.

Scientific collaborations
vials seen from above